Pakistan is among the developing countries which are experiencing a rising burden of hepatitis C with the prevalence rate of 4.5 to 8% thus making it as a huge disease burden for the country. Besides the continuously increasing disease prevalence, the treatment is very costly. After 2011, there has been advancement in the treatment. The new drugs have been found to be more effective with increased cure rates and less cost. So this study is aimed at conducting the cost effectiveness for hepatitis C treatments in patients with type 3 geno type.The costs and outcomes of providing treatment through intervention strategy is compared to the costs and outcomes of providing it through comparative strategy from provider perspective with the sample size of 697 patients. A decision analytic model i.e., Markov model is used for the analysis. The study has obtained the patient’s and cost data through hospital records and meta-analysis for the year 2016-17. The study findings indicate that the intervention is more effective in term of both costs and effects in comparison to the comparator in terms of incremental cost-effectiveness ratio. And the life years gained through intervention strategy are 5.86 years more than the comparative strategy. So providing hepatitis C treatment through intervention is a good public health investment in the elimination of virus from the country. Supervisor:- Dr. Jehangir Khan